within Pharmacolibrary.Drugs.ATC.J;

model J01XB02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.7166666666666665e-05,
    adminDuration  = 600,
    adminMass      = 1.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00034,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00047,
    k12             = 2.73,
    k21             = 2.73
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01XB02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Polymyxin B is a polypeptide antibiotic primarily active against Gram-negative bacteria. It is used to treat severe infections caused by multidrug-resistant organisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii, and other carbapenem-resistant Enterobacteriaceae. The drug is reserved for infections where alternatives are not suitable due to its nephrotoxicity and neurotoxicity. Polymyxin B is still clinically used today, predominantly in hospital settings.</p><h4>Pharmacokinetics</h4><p>Adult critically ill patients, population pharmacokinetic analysis.</p><h4>References</h4><ol><li><p>Tran, TB, et al., &amp; Li, J (2016). Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?. <i>International journal of antimicrobial agents</i> 48(6) 592–597. DOI:<a href=\"https://doi.org/10.1016/j.ijantimicag.2016.09.010\">10.1016/j.ijantimicag.2016.09.010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27793510/\">https://pubmed.ncbi.nlm.nih.gov/27793510</a></p></li><li><p>Kubin, CJ, et al., &amp; Yin, MT (2018). Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. <i>Antimicrobial agents and chemotherapy</i> 62(3) –. DOI:<a href=\"https://doi.org/10.1128/AAC.01493-17\">10.1128/AAC.01493-17</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29311066/\">https://pubmed.ncbi.nlm.nih.gov/29311066</a></p></li><li><p>Yu, Z, et al., &amp; Yu, Y (2025). Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant gram-negative bacterial infections: a prospective observational multicenter study. <i>Antimicrobial agents and chemotherapy</i> 69(4) e0185924–None. DOI:<a href=\"https://doi.org/10.1128/aac.01859-24\">10.1128/aac.01859-24</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40047414/\">https://pubmed.ncbi.nlm.nih.gov/40047414</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01XB02;
